Press Releases Items Per Page 102550 Year None202020192018201720162015201420132012201120102007 02.25.20 Syndax to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 3, 2020 02.18.20 Syndax Announces Participation at Two Upcoming Investor Conferences 01.31.20 Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million 01.30.20 Science Magazine Publishes Results from Preclinical Study on the Activity of Menin-MLL Inhibition for the Treatment of NPM1 Acute Myeloid Leukemia 01.10.20 Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook 12.10.19 Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease 12.09.19 Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias 11.07.19 Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update 11.06.19 Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias 10.31.19 Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019 08.28.19 Syndax Announces Participation at Four Upcoming Investor Conferences 08.07.19 Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
02.25.20 Syndax to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 3, 2020
01.31.20 Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million
01.30.20 Science Magazine Publishes Results from Preclinical Study on the Activity of Menin-MLL Inhibition for the Treatment of NPM1 Acute Myeloid Leukemia
12.10.19 Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease
12.09.19 Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias
11.07.19 Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update
11.06.19 Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
10.31.19 Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019
08.07.19 Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update
